Search Results

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

Impel NeuroPharma announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022.

Impel NeuroPharma announced two separate transactions with funds managed by Oaktree Capital Management, L.P. totaling $100 million in gross funding.

PurMinds NeuroPharma to initiate preclinical development of lead candidate PUR501 in 2024 in preparation for IND submission

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022 at 1:30 p.m. ET.

PurMinds NeuroPharma (“PurMinds™" or the “Company”), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders

Impel NeuroPharma today provided updates on Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) launch progress and recent business highlights.

Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced planned poster presentations at the upcoming American Academy of Neurology (AAN) annual meeting.

PurMinds NeuroPharma Inc. (“PurMinds™" or the “Company”), a clinical-stage neuroscience company dedicated to the development of innovative therapies for neurological and neurodegenerative disorders

Impel NeuroPharma (NASDAQ: IMPL), today announced it will host a live webcast on Thursday, March 24, 2022, at 8:30 a.m. ET to report its fourth quarter and full year 2021 financial results and provide a business update.